{"name": "Zealand Pharma",
 "permalink": "zealand-pharma",
 "crunchbase_url": "http://www.crunchbase.com/company/zealand-pharma",
 "homepage_url": "http://www.zealandpharma.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@zealandpharma.com",
 "phone_number": "45-88-77-36-00",
 "description": "Biotechnology company",
 "created_at": "Tue Feb 12 05:36:25 UTC 2013",
 "updated_at": "Tue Feb 12 05:40:47 UTC 2013",
 "overview": "\u003Cp\u003EZealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company\u2019s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide (Lyxumia\u00ae 1), a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is currently under regulatory review in a large number of countries globally, and in November 2012 the European Committee for Human Medicinal Products issued a positive recommendation for approval of the product in Europe.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       55],
      "assets/images/resized/0023/5283/235283v1-max-150x150.jpg"],
     [[185,
       68],
      "assets/images/resized/0023/5283/235283v1-max-250x250.jpg"],
     [[185,
       68],
      "assets/images/resized/0023/5283/235283v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "chairman of the supervisory board",
    "person":
     {"first_name": "Daan",
      "last_name": "Ellens",
      "permalink": "daan-ellens",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5891/275891v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5891/275891v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5891/275891v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board memeber",
    "person":
     {"first_name": "R\u00e9mi",
      "last_name": "Droller",
      "permalink": "rmi-droller",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5900/275900v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5900/275900v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5900/275900v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Smedeland 36 ",
    "address2": "",
    "zip_code": "2600",
    "city": "Copenhagen",
    "state_code": null,
    "country_code": "DNK",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        119],
       "assets/images/resized/0023/5284/235284v1-max-150x150.jpg"],
      [[250,
        198],
       "assets/images/resized/0023/5284/235284v1-max-250x250.jpg"],
      [[450,
        357],
       "assets/images/resized/0023/5284/235284v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}